The announcement of financial results is a regular event for publicly traded companies. While it highlights Ekso Bionics' leadership in its field, the article does not provide specific details on financial performance metrics such as revenue growth or profitability, which would be necessary to determine a more precise impact on stock price. Therefore, the short-term impact is considered neutral.